Ecnoglutide Phase 3 trial (NCT05813795)
A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 664
- actual
- Start
- 5 Apr 2023 (actual)
- Primary completion
- 20 Jun 2024 (actual)
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| C1- XW003 Low Dosage | Experimental | Drug: Ecnoglutide Low Dosage | XW003 with low dosage once weekly |
| C1-Placebo | Placebo comparator | Drug: Placebo | Matched Placebo once weekly |
| C2- XW003 Medium Dosage | Experimental | Drug: Ecnoglutide Medium Dosage | XW003 with medium dosage once weekly |
| C2-Placebo | Placebo comparator | Drug: Placebo | Matched Placebo once weekly |
| C3- XW003 High Dosage | Experimental | Drug: Ecnoglutide High Dosage | XW003 with high dosage once weekly |
| C3-Placebo | Placebo comparator | Drug: Placebo | Matched Placebo once weekly |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent change in body weight from baseline | Week 40 |
| Proportion of subjects with weight loss ≥5% from baseline | Week 40 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percent and absolute body weight change from baseline | Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48 |
| Proportion of subjects with weight loss ≥ 5%, 10%, 15% from baseline | Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48 |
| Change from baseline in BMI | Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48 |
| Change from baseline in waist and hip circumferences | Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.